Nierenberg Investment Management Company LLC Purchases New Stake in Haemonetics Corporation $HAE

Nierenberg Investment Management Company LLC acquired a new position in shares of Haemonetics Corporation (NYSE:HAE) during the 2nd quarter, Holdings Channel.com reports. The firm acquired 26,280 shares of the medical instruments supplier’s stock, valued at approximately $1,971,000,000. Haemonetics accounts for about 1.0% of Nierenberg Investment Management Company LLC’s investment portfolio, making the stock its 15th largest holding.

A number of other hedge funds have also recently added to or reduced their stakes in the business. Kemnay Advisory Services Inc. bought a new stake in Haemonetics during the fourth quarter valued at $26,000. Leonteq Securities AG acquired a new stake in shares of Haemonetics during the fourth quarter worth $30,000. EverSource Wealth Advisors LLC lifted its position in shares of Haemonetics by 2,640.0% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 411 shares of the medical instruments supplier’s stock worth $31,000 after buying an additional 396 shares during the last quarter. Kestra Advisory Services LLC acquired a new position in shares of Haemonetics in the 4th quarter valued at about $34,000. Finally, Kelleher Financial Advisors acquired a new position in shares of Haemonetics in the 2nd quarter valued at about $38,000. Institutional investors and hedge funds own 99.67% of the company’s stock.

Haemonetics Trading Up 3.6%

Shares of NYSE:HAE opened at $108.39 on Thursday. The company has a market cap of $4.93 billion, a PE ratio of 53.14, a P/E/G ratio of 2.10 and a beta of 0.52. The company’s 50-day moving average price is $80.50 and its 200 day moving average price is $67.90. Haemonetics Corporation has a fifty-two week low of $47.31 and a fifty-two week high of $108.50. The company has a quick ratio of 1.91, a current ratio of 3.08 and a debt-to-equity ratio of 1.40.

Haemonetics (NYSE:HAE) last posted its earnings results on Thursday, August 6th. The medical instruments supplier reported $1.14 EPS for the quarter, topping the consensus estimate of $1.08 by $0.06. Haemonetics had a net margin of 7.12% and a return on equity of 27.55%. The firm had revenue of $339.38 million during the quarter, compared to analysts’ expectations of $327.86 million. During the same quarter in the prior year, the firm earned $1.10 EPS. Haemonetics’s quarterly revenue was up 5.5% on a year-over-year basis. Sell-side analysts anticipate that Haemonetics Corporation will post 5.28 earnings per share for the current year.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on HAE shares. BTIG Research increased their price objective on shares of Haemonetics from $96.00 to $110.00 and gave the stock a “buy” rating in a research note on Tuesday. Barrington Research lifted their target price on Haemonetics from $95.00 to $118.00 and gave the company an “outperform” rating in a research note on Wednesday. Wall Street Zen raised Haemonetics from a “buy” rating to a “strong-buy” rating in a report on Saturday, August 8th. Robert W. Baird set a $96.00 target price on Haemonetics in a report on Friday, August 7th. Finally, Mizuho increased their price target on Haemonetics from $85.00 to $90.00 and gave the stock an “outperform” rating in a research report on Wednesday, July 15th. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and four have given a Hold rating to the stock. According to data from MarketBeat, Haemonetics has an average rating of “Moderate Buy” and an average target price of $95.00.

Trending Headlines about Haemonetics

Here are the key news stories impacting Haemonetics this week:

• Positive Sentiment: New CSL Plasma supply agreement: Haemonetics signed a non-exclusive agreement to supply CSL Plasma’s U.S. collection operations. The deal restores business with a major customer after a prior supply transition weighed on results, potentially improving revenue visibility and supporting the company’s plasma-collection franchise. Haemonetics reconnects with CSL in US plasma collection deal
• Positive Sentiment: Raised fiscal 2027 outlook and solid quarterly results: Haemonetics reported quarterly revenue of $339.4 million, up approximately 5.6% year over year, while adjusted EPS rose to $1.14 and exceeded consensus. Management raised its full-year reported revenue-growth forecast to 5%–8% from 4%–7%, with plasma revenue and adoption of Persona PLUS on the NexSys PCS platform providing momentum. Haemonetics Jumps as Investors Cheer Raised Fiscal 2027 Outlook
• Positive Sentiment: Analyst support: BTIG raised its price target from $96 to $110 and maintained a Buy rating, reinforcing bullish momentum. BTIG raises Haemonetics price target

About Haemonetics

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company’s offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company’s product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.